What does StemRIM do?
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis,…
What is StemRIM's P/E and P/B ratio?
StemRIM has a P/E ratio of -4.8 and a P/B ratio of 1.46.
What is StemRIM's debt-to-equity ratio?
StemRIM has a debt-to-equity ratio of 0.00.
How much does StemRIM owe compared with what it owns?
StemRIM owes ¥0.04 for every ¥1 it owns (balance sheet Apr 2026), which is low.
What is StemRIM's Positivity rank?
StemRIM is ranked #3,041 of 10,749 companies globally and #1,382 of 3,683 in Japan on PositoAI, with a Positivity Score of 22,751.
Does StemRIM have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for StemRIM.
Where can I read the latest news about StemRIM?
Recent headlines about StemRIM from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does StemRIM have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of StemRIM's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.